FRISCO, Texas, Oct. 18, 2016 -- Integer Holdings Corporation (NYSE:ITGR), a leading medical device outsource (MDO) manufacturer, today announced that Donald Spence has been elected to Integer’s Board of Directors. Mr. Spence also will serve on the Board’s Science and Technology Committee.
“We would like to welcome Don to our Board of Directors,” said Bill R. Sanford, Integer’s chairman of the board. “Don brings strong operational and executive management experience along with an extensive background in the medical device industry which will further strengthen and complement the overall depth of our already experienced Board.”
“I worked closely with Don to combine Lake Region Medical and Greatbatch into a Medical Device Outsourcing leader. He was a primary and pivotal advocate for the deal and continues to be a staunch supporter of Integer’s vision,” commented Thomas J. Hook, Integer’s president and chief executive officer. “I look forward to working together with Don and the other Integer Board members as we execute our strategy and grow our business to deliver increased value for our shareholders. His knowledge and insights will make a significant contribution to the corporate governance and board oversight of our company.”
Mr. Spence brings 40 years of experience including over 25 years in the medical device industry, in operations, finance, and general management roles. He most recently served as chairman and chief executive officer of Lake Region Medical from 2010 until its acquisition by the Company in October of 2015. From 2005 to 2008 he served as president of the Sleep and Home Respiratory Group for Philips Respironics, and from 2008 to 2010 as chief executive officer of Philips Home Healthcare Solutions. Prior to that, Mr. Spence spent eight years with GKN Sinter Metals, as senior vice president for global sales and marketing (1998-2001) and as president (2001-2005). Before 1998, he served in a number of roles at BOC Group, PLC over a 15-year career at that company. Mr. Spence also serves on the board of directors of two privately held Medtech companies.
About Integer
Integer Holdings Corporation (ITGR) is one of the largest medical device outsource (MDO) manufacturers in the world serving the cardiac, neuromodulation, orthopedics, vascular, advanced surgical and portable medical markets. The company provides innovative, high-quality medical technologies that enhance the lives of patients worldwide. In addition, it develops batteries for high-end niche applications in energy, military, and environmental markets. The company's brands include Greatbatch Medical, Lake Region Medical and Electrochem. Additional information is available at www.integer.net.
Investor Relations: Amy Wakeham [email protected] 214.618.4978 Media Relations: Kelly Butler [email protected] 214.618.4216


Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Instagram Outage Disrupts Thousands of U.S. Users
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 



